BioCentury
ARTICLE | Clinical News

ZP4207 in rescue pen: Phase I data

July 13, 2015 7:00 AM UTC

A German Phase I trial in 64 healthy volunteers and 20 Type I diabetics showed that single doses of 0.01-2 mg ZP4207 were well tolerated. Additionally, ZP4207 increased blood glucose levels after insu...